BeiGene $BGNE has released its quarterly earnings, reporting a revenue of $1.00 billion, which represents a 28.25% year-over-year increase, beating estimates by $40.06 million. The company's earnings per share (EPS) were -$1.15, surpassing expectations by $0.09. Additionally, BeiGene has unveiled a proposed name change to BeOne Medicines, aiming to reaffirm its mission to unite the global community against cancer. Following the announcement, BeiGene shares rose by 1.87% in premarket trading.